C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/38 (2006.01) A61K 39/245 (2006.01) A61P 31/20 (2006.01) A61P 37/04 (2006.01) C07K 14/045 (2006.01) C12N 15/85 (2006.01) C12N 15/87 (2006.01)
Patent
CA 2756797
The invention is related to polynucleotide-based cytomegalovirus vaccines. In particular, the invention is plasmids operably encoding HCMV antigens, in which the naturally- occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens which are useful in the invention include, but are not limited to pp65, glycoprotein B (gB), IE1, and fragments, variants or derivatives of either of these antigens. In certain embodiments, sequences have been deleted, e.g., the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB. The invention is further directed to methods to induce an immune response to HCMV in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized. HCMV antigen as described above. The invention is also directed to pharmaceutical compositions comprising plasmids encoding a codon-optimized HCMV antigen as described above, and further comprising adjuvants, excipients, or immune modulators.
Geall Andrew J.
Hermanson Gary G.
Wloch Mary Kopke
Mbm Intellectual Property Law Llp
Vical Incorporated
LandOfFree
Codon-optimized polynucleotide-based vaccines against human... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Codon-optimized polynucleotide-based vaccines against human..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Codon-optimized polynucleotide-based vaccines against human... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1532535